Given the failure to develop disease-modifying therapies for Alzheimer's disease (AD),
strategies aiming at preventing or delaying the onset of the disease are being prioritized …

Mounting evidence accumulated over the past few years indicates that the neurotransmitter
serotonin plays a significant role in cognition. As a drug target, serotonin receptors have …

Depression is a common co-morbidity seen in people with Alzheimer's disease (AD).
However, the successful treatment of depressive symptoms in people with AD is rarely seen …

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive
memory loss along with neuropsychiatric symptoms and a decline in activities of daily life. Its …

It is broadly acknowledged that the onset of dementia in Alzheimer's disease (AD) may be
modifiable by the management of risk factors. While several recent guidelines and …

There is a high prevalence rate (30-50%) of Alzheimer's disease (AD) and depression
comorbidity. Depression can be a risk factor for the development of AD or it can be …

Objective Selective serotonin reuptake inhibitors (SSRIs) have increased cognitive
performance in some clinical studies of Alzheimer's disease (AD), but it is has been difficult …

Objectives A series of preclinical studies have suggested that selective serotonin reuptake
inhibitor antidepressants not only stimulate neurogenesis but also have neuroprotective …

Serotonin signaling suppresses generation of amyloid-β (Aβ) in vitro and in animal models
of Alzheimer's disease (AD). We show that in an aged transgenic AD mouse model …

Alzheimer's disease (AD) is the most common cause of dementia in elderly people.
Research focused on identifying compounds that restore cognition and memory in AD …